Health Care [ 9/12 ] | Biotechnology [ 51/74 ]
NASDAQ | Common Stock
Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases.
The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease.
It has a license agreement with The University of Edinburgh, Virovek, Inc., Sigma-Aldrich Co. LLC., and Leland Stanford Junior University.
The company was founded in 2018 and is headquartered in New York, New York.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 13, 26 | -1.39 Decreased by -28.41% | -1.27 Decreased by -9.05% |
| Mar 24, 26 | -1.13 Decreased by -14.14% | -1.24 Increased by +8.69% |
| Nov 13, 25 | -0.99 Increased by +16.98% | -1.18 Increased by +16.10% |
| Aug 11, 25 | -1.05 Increased by +3.67% | -1.11 Increased by +5.41% |
| May 8, 25 | -1.08 Decreased by -8.00% | -1.12 Increased by +3.57% |
| Mar 17, 25 | -0.99 Increased by +34.44% | -1.13 Increased by +12.26% |
| Nov 12, 24 | -1.19 Decreased by -192.49% | -1.22 Increased by +2.25% |
| Aug 9, 24 | -1.09 Decreased by -2.63 K% | -1.05 Decreased by -3.81% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 26 | 0.00 Decreased by N/A% | -30.93 M Decreased by -36.59% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 25 | 0.00 Increased by +100.00% | -24.73 M Decreased by -26.76% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 25 | 0.00 Decreased by N/A% | -20.95 M Decreased by -3.64% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 25 | 0.00 Decreased by -100.00% | -22.02 M Decreased by -19.06% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 25 | 0.00 Decreased by N/A% | -22.65 M Decreased by -33.84% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 24 | -925.00 K Decreased by N/A% | -19.51 M Decreased by -918.88% | Increased by +2.11 K% Decreased by N/A% |
| Sep 30, 24 | 0.00 Decreased by N/A% | -20.22 M Decreased by -38.69% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 925.00 K Increased by +N/A% | -18.49 M Decreased by -55.92% | Decreased by -2.00 K% Decreased by N/A% |